Clinical Trial Update: A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 efficacy trial of PRX-00023 in Major Depressive Disorder has been completed. The study was sponsored by Epix Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• PRX-00023

Snippet

Sponsor: Epix Pharmaceuticals, Inc. | Conditions: Major Depressive Disorder (MDD) | Phase 2 | Status: COMPLETED